# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Wolfe Research analyst Andy Chen upgrades Ionis Pharmaceuticals (NASDAQ:IONS) from Peer Perform to Outperform.
Oppenheimer analyst Jay Olson maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Outperform and raises the price target fr...
Needham analyst Joseph Stringer reiterates Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and maintains $60 price target.
– Olezarsen met the primary endpoint with statistically significant reduction of fasting triglycerides and showed subst...
– First presentation of pivotal results showing significant reduction in triglycerides and substantial reduction in acute panc...
Ionis Pharmaceuticals reports positive Phase 2 results for ION224, showing significant improvement in MASH and liver histology ...
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) announced positive results from a Phase 2 study of ION224, an investigational DGAT2 ...
Oppenheimer analyst Jay Olson maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Outperform and raises the price target fr...